Is Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) safe to use in patients with severe hepatic impairment (Child‑Pugh C) or liver failure?

Biktarvy in Severe Hepatic Impairment (Child-Pugh C)

Biktarvy is NOT recommended in patients with severe hepatic impairment (Child-Pugh Class C) and should be avoided in liver failure. 1

Primary Recommendation

The FDA drug label explicitly states that Biktarvy has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and is therefore not recommended for use in this population 1. This is a clear contraindication based on lack of safety and pharmacokinetic data rather than documented harm, but the absence of data in this critically ill population makes use inadvisable.

Supporting Guideline Evidence

The 2020 International Antiviral Society-USA (IAS-USA) guidelines in JAMA provide additional context: protease inhibitors (PIs) and integrase strand transfer inhibitors (InSTIs) should be used with caution in patients with severe hepatic impairment (Child-Pugh C disease) 2. Since bictegravir is an INSTI, this guideline reinforces the cautious approach. Importantly, the guidelines note that no dose adjustment is required for mild to moderate hepatic impairment (Child-Pugh A or B) 2.

Dosing by Hepatic Function

• Mild hepatic impairment (Child-Pugh A): No dose adjustment needed 1
• Moderate hepatic impairment (Child-Pugh B): No dose adjustment needed 1
• Severe hepatic impairment (Child-Pugh C): NOT recommended - avoid use 1

Alternative Agents for Severe Hepatic Impairment

The IAS-USA guidelines specifically identify antiretrovirals that do NOT require dose adjustment in severe hepatic impairment 2:

• Tenofovir (either formulation)
• Lamivudine
• Raltegravir (an INSTI)
• Rilpivirine

These agents would be preferred alternatives when constructing a regimen for patients with Child-Pugh C cirrhosis or liver failure.

Clinical Context from Research

While tenofovir alafenamide (TAF, a component of Biktarvy) has been studied in hepatic impairment for hepatitis B treatment, the available data specifically excludes severe impairment. One study notes that TAF "is safe in patients with mild hepatic impairment but is not currently recommended in patients with moderate or severe hepatic impairment (Child-Pugh class B or C)" 3. However, a more recent 2024 study did evaluate switching to TAF in patients with hepatic impairment including decompensation (Child-Pugh scores 7-12, which includes some Child-Pugh C patients), showing maintained viral suppression and stable liver enzymes at 96 weeks 4. Despite this, the FDA has not changed its labeling for Biktarvy based on this hepatitis B data.

Critical Pitfalls to Avoid

1. Do not assume safety based on individual components: Even though tenofovir doesn't require dose adjustment in severe hepatic impairment, bictegravir (the INSTI component) has not been adequately studied in this population
2. Do not confuse Child-Pugh B with C: Biktarvy is acceptable in moderate impairment (Child-Pugh B) but not severe (Child-Pugh C)
3. Hepatitis B coinfection consideration: If the patient has HIV/HBV coinfection and severe hepatic impairment, you'll need a regimen that covers both viruses - consider raltegravir + tenofovir + lamivudine or emtricitabine as alternatives

Practical Algorithm

For patients with severe hepatic impairment needing HIV treatment:

1. Confirm Child-Pugh score is truly Class C (score 10-15)
2. Avoid Biktarvy - use alternative regimen
3. Select from hepatically-safe agents: raltegravir + tenofovir (TDF or TAF) + lamivudine/emtricitabine
4. If HBV coinfection present, ensure regimen includes tenofovir + lamivudine or emtricitabine
5. Monitor closely for hepatic decompensation and consider hepatology co-management